# Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions

> **NCT00974012** · PHASE1 · COMPLETED · sponsor: **Teva Pharmaceuticals USA** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Divalproex Sodium
- **DRUG:** Depakote®

## Key facts

- **NCT ID:** NCT00974012
- **Lead sponsor:** Teva Pharmaceuticals USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2009-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00974012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00974012, "Divalproex Sodium 500 mg Extended Release Tablets Under Non-Fasting Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00974012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*